Searching for Solutions

The xylazine toolkit, intended to highlight the evidence base available and strategies of clinical decision making, was recently updated by AAPP member Sarah Thomason to include sections on regulatory status, laboratory testing and wound care.

In this year’s report, OCP celebrates its 30th anniversary, showcasing the Office’s contributions to the evolution of clinical pharmacology into a foundational pillar of drug development and regulatory review by enhancing efficacy and safety evaluations through rigorous, collaborative, and state-of-the-art approaches.

US adults likely have heterogenous views on addiction, and more research is needed to further understand how US adults conceptualize addiction.

In this study, SROM for OUD was associated with slightly higher treatment discontinuation risk than methadone but similar mortality risk, suggesting either medication may be appropriate alongside measures to support retention.

Stimulant-induced psychosis occurs in both therapeutic and nontherapeutic contexts but at vastly different prevalence rates.

While both PWUF and clinicians identified precipitated withdrawal as a major concern when initiating buprenorphine, it was just one of many barriers.

This paper provides an overview of SED, including the role of functional impairment in identifying youth with SED and the important developmental considerations.

This report provides a guide to publicly accessible data sources to support research and improve data-driven decision-making for individuals dually eligible for Medicaid and Medicare.

State Medicaid expansions from 2017 to 2023 increased access to medication treatment for opioid use disorder at a time when fatal overdoses were continuing to climb, researchers wrote in JAMA Network Open. That means coverage expansions can significantly affect uptake of addiction medicine like buprenorphine. The findings could be important for state governments wrestling with reductions in federal Medicaid spending.

Collegiate Chapter Impact Grant recipients will share their grant-funded projects during the Collegiate Chapter Meeting on Sunday, 4/19! Join chapter representatives in the Cedar Ballroom from 4:45-5:15 PM Pacific Time. Presentations will not be livestreamed; however, they will be recorded and posted for those unable to attend live. Thank you to our donors for helping us continue this important grant program with your monetary gifts.

Thanks to generous AAPP Foundation donors and the AAPP Past Presidents' Destiny Fund, 33 PharmD students were awarded full, in-person student registration grants to AAPP 2026! Congratulations to each of the recipients and enjoy your time in Seattle!

Momentum continued throughout 2025 in the areas of grant support, practitioner development, and sponsorship! View our 2025 Annual Report to see the impact. Thank you to the incredible donors who support this important work.

No summary available

No summary available

Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. Pharmacists who focus on psychiatric and neurologic diseases improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Read this MHC article to learn more about the value of psychiatric and neurologic pharmacists as part of the health care team.

Access valuable psychiatric treatment guideline and clinical pearl resources at AAPP